Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?
- Study type
- Other
- Design
- Comment on a paper published in the same journal (Lancet 2025;405:839-849); the PubMed record has no abstract
- Source
- The Lancet · 2025
In plain words
This piece gives the opinion of two cancer specialists about the drug ivonescimab in advanced non-small-cell lung cancer. The main question is whether showing that the disease is kept under control for longer (progression-free survival) is enough, or whether it must also be proven that patients live longer (overall survival). To make decisions about treatment, talk with your own doctor.
Study population
The PubMed record has no abstract and gives no information on the patient population. The title refers to advanced non-small-cell lung cancer (NSCLC).
Endpoints
No abstract is available. The title raises the question of whether progression-free survival (PFS) alone is enough to evaluate ivonescimab in advanced NSCLC or whether overall survival (OS) data are also needed.
Safety and side effects
The PubMed record contains no information on adverse events.
Clinical significance and place in guidelines
The PubMed record has no abstract, and no conclusion about changes in practice can be drawn from it. This paper is a comment, not a trial. Its title stresses the importance of overall survival data alongside progression-free survival when evaluating ivonescimab. The drug's approval status and its place in clinical guidelines should be checked in separate sources.
Limitations
Neither an abstract nor the full text is available in the record, so the authors' arguments, data and conclusions cannot be reported. This card was prepared only from the title and bibliographic information; the full text should be consulted for details.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.